Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase II trial of the Eastern Cooperative Oncology Group

BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). We sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic S...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Argiris, Athanassios, Buchanan, Ashley, Brockstein, Bruce, Kolesar, Jill, Ghebremichael, Musie, Pins, Michael, Hahn, Kristine, Axelrod, Rita, Forastiere, Arlene
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2749918/
https://ncbi.nlm.nih.gov/pubmed/19634157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24528
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares